Angelica Cheng
Active Member
Here are recommendations on PGT-A by the American Society for Reproductive Medicine (ASRM) Practice Committee, which was just published in September 2024.
In summary, the ASRM concluded that the overall pregnancy outcomes were similar between IVF cycles with and without PGT-A. The value of PGT-A to lower the risk of clinical miscarriage is also unclear.
Additionally, I also enclose a second article that questions why the routine clinical utilization of PGT-A should continue if the technique does not improve IVF cycle outcomes.
These two PDF files are hereby attached.
pubmed.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
The use of preimplantation genetic testing for aneuploidy: a committee opinion (Fertility & Sterility Volume 122, Issue 3, p421-434, September 2024)
Abstract
The use of preimplantation genetic testing for aneuploidy (PGT-A) in the United States has been increasing steadily. Moreover, the underlying technology used for 24-chromosome analysis continues to evolve rapidly. The value of PGT-A as a routine screening test for all patients undergoing in vitro fertilization has not been demonstrated. Although some earlier single-center studies reported higher live-birth rates after PGT-A in favorable-prognosis patients, recent multicenter, randomized control trials in women with available blastocysts concluded that the overall pregnancy outcomes via frozen embryo transfer were similar between PGT-A and conventional in vitro fertilization. The value of PGT-A to lower the risk of clinical miscarriage is also unclear, although these studies have important limitations. This document replaces the document of the same name, last published in 2018.
An additive opinion to the committee opinion of ASRM and SART on the use of preimplantation genetic testing for aneuploidy (PGT-A) (J Assist Reprod Genet.2024 Dec 18.)
Abstract
After over 20 years of progressively increasing clinical utilization of PGT-A (and its precursors), the American Society for Reproductive Medicine (ASRM) and its daughter society, the Society for Assisted Reproduction (SART), for the first time published a committee opinion clearly acknowledging that "the value of PGT-A as a routine screening test for patients undergoing in vitro fertilization (IVF) has not been demonstrated." This statement is timely and welcome but requires some additions and raises some new questions, among those why, if PGT-A in a general population does not improve IVF cycle outcomes, the routine clinical utilization of PGT-A should continue.
In summary, the ASRM concluded that the overall pregnancy outcomes were similar between IVF cycles with and without PGT-A. The value of PGT-A to lower the risk of clinical miscarriage is also unclear.
Additionally, I also enclose a second article that questions why the routine clinical utilization of PGT-A should continue if the technique does not improve IVF cycle outcomes.
These two PDF files are hereby attached.

The use of preimplantation genetic testing for aneuploidy: a committee opinion - PubMed
The use of preimplantation genetic testing for aneuploidy (PGT-A) in the United States has been increasing steadily. Moreover, the underlying technology used for 24-chromosome analysis continues to evolve rapidly. The value of PGT-A as a routine screening test for all patients undergoing in...


An additive opinion to the committee opinion of ASRM and SART on the use of preimplantation genetic testing for aneuploidy (PGT-A) - PubMed
After over 20 years of progressively increasing clinical utilization of PGT-A (and its precursors), the American Society for Reproductive Medicine (ASRM) and its daughter society, the Society for Assisted Reproduction (SART), for the first time published a committee opinion clearly acknowledging...

The use of preimplantation genetic testing for aneuploidy: a committee opinion (Fertility & Sterility Volume 122, Issue 3, p421-434, September 2024)
Abstract
The use of preimplantation genetic testing for aneuploidy (PGT-A) in the United States has been increasing steadily. Moreover, the underlying technology used for 24-chromosome analysis continues to evolve rapidly. The value of PGT-A as a routine screening test for all patients undergoing in vitro fertilization has not been demonstrated. Although some earlier single-center studies reported higher live-birth rates after PGT-A in favorable-prognosis patients, recent multicenter, randomized control trials in women with available blastocysts concluded that the overall pregnancy outcomes via frozen embryo transfer were similar between PGT-A and conventional in vitro fertilization. The value of PGT-A to lower the risk of clinical miscarriage is also unclear, although these studies have important limitations. This document replaces the document of the same name, last published in 2018.
An additive opinion to the committee opinion of ASRM and SART on the use of preimplantation genetic testing for aneuploidy (PGT-A) (J Assist Reprod Genet.2024 Dec 18.)
Abstract
After over 20 years of progressively increasing clinical utilization of PGT-A (and its precursors), the American Society for Reproductive Medicine (ASRM) and its daughter society, the Society for Assisted Reproduction (SART), for the first time published a committee opinion clearly acknowledging that "the value of PGT-A as a routine screening test for patients undergoing in vitro fertilization (IVF) has not been demonstrated." This statement is timely and welcome but requires some additions and raises some new questions, among those why, if PGT-A in a general population does not improve IVF cycle outcomes, the routine clinical utilization of PGT-A should continue.